Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 8Carcinoid Tumor 3Acromegaly 3Pituitary Neoplasms 2Neoplasm Metastasis 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Hepatocellular 2Pheochromocytoma 1Paraganglioma 1Neoplastic Cells, Circulating 1Neoplasms 1Growth Hormone-Secreting Pituitary Adenoma 1Gigantism 1Gastrointestinal Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Sorafenib 131lenvatinib 115Bevacizumab 88Radiosurgery 69atezolizumab 55sintilimab 54Nivolumab 51durvalumab 43Hepatectomy 43Fluorouracil 42apatinib 41Oxaliplatin 41camrelizumab 38Radiofrequency Ablation 38pembrolizumab 36Radiotherapy 36tislelizumab 35Leucovorin 31Magnetic Resonance Spectroscopy 30Immune Checkpoint Inhibitors 28Doxorubicin 28Folfox protocol 26tremelimumab 25regorafenib 25Cisplatin 20spartalizumab 19donafenib 19Gemcitabine 19Cyclophosphamide 19toripalimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Hepatocellular × lanreotide × Clear all
NCT02973204 2021-04-28

Circulating Tumor Cells and Tumor DNA in HCC and NET

University of Aarhus

Completed
167 enrolled
EndocrineGastrointestinalNET

Carcinoma, Hepatocellular, Neoplastic Cells, Circulating, Neuroendocrine Tumors

NCT00495846 2009-08-17

SS-HCC

Federico II University

Phase 2/3 Completed
25 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡